174 related articles for article (PubMed ID: 28094098)
1. Altered balance of epidermis-related chemokines in epidermolysis bullosa.
Ujiie I; Fujita Y; Nakayama C; Matsumura W; Suzuki S; Shinkuma S; Nomura T; Abe R; Shimizu H
J Dermatol Sci; 2017 Apr; 86(1):37-45. PubMed ID: 28094098
[TBL] [Abstract][Full Text] [Related]
2. CTACK/CCL27 accelerates skin regeneration via accumulation of bone marrow-derived keratinocytes.
Inokuma D; Abe R; Fujita Y; Sasaki M; Shibaki A; Nakamura H; McMillan JR; Shimizu T; Shimizu H
Stem Cells; 2006 Dec; 24(12):2810-6. PubMed ID: 16931770
[TBL] [Abstract][Full Text] [Related]
3. Recessive dystrophic epidermolysis bullosa skin displays a chronic growth-activated immunophenotype. Implications for carcinogenesis.
Smoller BA; McNutt NS; Carter DM; Gottlieb AB; Hsu A; Krueger J
Arch Dermatol; 1990 Jan; 126(1):78-83. PubMed ID: 1688702
[TBL] [Abstract][Full Text] [Related]
4. Flightless I over-expression impairs skin barrier development, function and recovery following skin blistering.
Kopecki Z; Yang GN; Arkell RM; Jackson JE; Melville E; Iwata H; Ludwig RJ; Zillikens D; Murrell DF; Cowin AJ
J Pathol; 2014 Apr; 232(5):541-52. PubMed ID: 24375017
[TBL] [Abstract][Full Text] [Related]
5. Using immunofluorescence (antigen) mapping in the diagnosis and classification of epidermolysis bullosa: a first report from Iran.
Barzegar M; Asadi-Kani Z; Mozafari N; Vahidnezhad H; Kariminejad A; Toossi P
Int J Dermatol; 2015 Oct; 54(10):e416-23. PubMed ID: 26220012
[TBL] [Abstract][Full Text] [Related]
6. Graftskin therapy in epidermolysis bullosa.
Fivenson DP; Scherschun L; Choucair M; Kukuruga D; Young J; Shwayder T
J Am Acad Dermatol; 2003 Jun; 48(6):886-92. PubMed ID: 12789180
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of high mobility group box 1 correlate with disease severity in recessive dystrophic epidermolysis bullosa.
Petrof G; Abdul-Wahab A; Proudfoot L; Pramanik R; Mellerio JE; McGrath JA
Exp Dermatol; 2013 Jun; 22(6):433-5. PubMed ID: 23711070
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of inherited epidermolysis bullosa in Romania and genotype-phenotype correlations in patients with dystrophic epidermolysis bullosa.
Dănescu S; Has C; Senila S; Ungureanu L; Cosgarea R
J Eur Acad Dermatol Venereol; 2015 May; 29(5):899-903. PubMed ID: 25201089
[TBL] [Abstract][Full Text] [Related]
9. Molecular therapies for inherited epidermolysis bullosa.
Has C
G Ital Dermatol Venereol; 2016 Aug; 151(4):397-402. PubMed ID: 27149615
[TBL] [Abstract][Full Text] [Related]
10. Ultrastructural findings in epidermolysis bullosa.
Smith LT
Arch Dermatol; 1993 Dec; 129(12):1578-84. PubMed ID: 7504435
[TBL] [Abstract][Full Text] [Related]
11. Pro-Inflammatory Chemokines and Cytokines Dominate the Blister Fluid Molecular Signature in Patients with Epidermolysis Bullosa and Affect Leukocyte and Stem Cell Migration.
Alexeev V; Salas-Alanis JC; Palisson F; Mukhtarzada L; Fortuna G; Uitto J; South A; Igoucheva O
J Invest Dermatol; 2017 Nov; 137(11):2298-2308. PubMed ID: 28736230
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology of epidermolysis bullosa in the antipodes: the Australasian Epidermolysis Bullosa Registry with a focus on Herlitz junctional epidermolysis bullosa.
Kho YC; Rhodes LM; Robertson SJ; Su J; Varigos G; Robertson I; Hogan P; Orchard D; Murrell DF
Arch Dermatol; 2010 Jun; 146(6):635-40. PubMed ID: 20566927
[TBL] [Abstract][Full Text] [Related]
13. Epidermolysis bullosa in Finland. Clinical features, morphology and relation to collagen metabolism.
Kero M
Acta Derm Venereol Suppl (Stockh); 1984; 110():1-51. PubMed ID: 6331034
[TBL] [Abstract][Full Text] [Related]
14. Wound management for children with epidermolysis bullosa.
Denyer JE
Dermatol Clin; 2010 Apr; 28(2):257-64, viii-ix. PubMed ID: 20447488
[TBL] [Abstract][Full Text] [Related]
15. Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI).
Loh CC; Kim J; Su JC; Daniel BS; Venugopal SS; Rhodes LM; Intong LR; Law MG; Murrell DF
J Am Acad Dermatol; 2014 Jan; 70(1):89-97.e1-13. PubMed ID: 24355263
[TBL] [Abstract][Full Text] [Related]
16. Analysis of chemotactic molecules in bone marrow-derived mesenchymal stem cells and the skin: Ccl27-Ccr10 axis as a basis for targeting to cutaneous tissues.
Alexeev V; Donahue A; Uitto J; Igoucheva O
Cytotherapy; 2013 Feb; 15(2):171-184.e1. PubMed ID: 23321329
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal complications of inherited epidermolysis bullosa: cumulative experience of the National Epidermolysis Bullosa Registry.
Fine JD; Johnson LB; Weiner M; Suchindran C
J Pediatr Gastroenterol Nutr; 2008 Feb; 46(2):147-58. PubMed ID: 18223373
[TBL] [Abstract][Full Text] [Related]
18. A comparative study between transmission electron microscopy and immunofluorescence mapping in the diagnosis of epidermolysis bullosa.
Yiasemides E; Walton J; Marr P; Villanueva EV; Murrell DF
Am J Dermatopathol; 2006 Oct; 28(5):387-94. PubMed ID: 17012912
[TBL] [Abstract][Full Text] [Related]
19. Skin cleansing and topical product use in patients with epidermolysis bullosa: Results from a multicenter database.
Shayegan LH; Levin LE; Galligan ER; Lucky AW; Bruckner AL; Pope E; Lara-Corrales I; Wiss K; McCuaig CC; Garzon MC; Eichenfield LF; Hook KP; Browning JC; Schachner LA; Perman MJ; Castelo-Soccio L; Levy ML; Glick SA; Morel KD
Pediatr Dermatol; 2020 Mar; 37(2):326-332. PubMed ID: 31944391
[TBL] [Abstract][Full Text] [Related]
20. Evaluation and treatment of the newborn with epidermolysis bullosa.
Gonzalez ME
Semin Perinatol; 2013 Feb; 37(1):32-9. PubMed ID: 23419761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
